Investegate |Lupin Ltd Announcements | Lupin Ltd: Lupin's Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

Investegate announcements from Lupin Ltd, Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

Related Keywords

United Kingdom ,Mumbai ,Maharashtra ,India ,South Africa ,Ben Ellis ,Asia Pacific ,Sukaina Virji ,Consortium For Clinical Investigation Of Neurologic Channelopathies ,National Institute For Health ,Lupin Healthcare United Kingdom ,Biotechnology Pharmaceuticals ,European Union ,Consilium Strategic Communications ,National Institute ,Care Excellence ,Final Appraisal Determination ,General Manager ,Lupin Healthcare United ,Non Dystrophic Myotonias ,Latin America ,Great Place ,Appraisal Document ,Raja Rayan ,Clinical Investigation ,Healthcare United Kingdom Limited ,Investegate Announcements ,Investegate Company Announcements ,Lupin Ltd ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,